Latest news with #IgG1
Business Wire
6 days ago
- Health
- Business Wire
Resolve Therapeutics and Duke Medical School Initiate Observational Study of Cell-free RNA in Polytrauma Patients
MIAMI--(BUSINESS WIRE)--Resolve Therapeutics, a leader in the emerging field of cell-free nucleic acid therapeutics, today announced a collaboration with the Department of Surgery, Duke University School of Medicine to analyze the role of cell-free RNA (cfRNA) in polytrauma A significant number of trauma patients admitted to the hospital each year suffer from polytrauma, with multiple, life-threatening injuries requiring immediate surgical intervention. Many of these patients experience poor clinical outcomes due to Systemic Inflammatory Response Syndrome (SIRS). The mechanism of SIRS in polytrauma patients is not completely understood but the current view holds that that massive tissue injury results in the release of large amounts of RNA into the blood overwhelming the activity of circulating RNase, which protects cells from the inflammatory effects of cfRNA under normal circumstances. The accumulating cfRNA activates several key mechanisms driving local and systemic inflammation which leads to increased morbidity and mortality. 'Preventing systemic inflammation in polytrauma would be a large step forward in the treatment paradigm for these patients,' said Allan D. Kirk, MD, PhD, Chair of the Department of Surgery at Duke University. Share Working closely with the world's foremost trauma surgeons at Duke University, Resolve and Duke will conduct an observational study to analyze the presence, structure, and drug targeting of cfRNA in a selected population of polytrauma patients. Based on the results of this work, a proof-of-concept clinical trial with RSLV-132 (a fully human, catalytically active, RNase Fc fusion protein) may be undertaken seeking to improve clinical outcomes for polytrauma patients by removing circulating inflammatory nucleic acids. 'We are thrilled to work with the world class physician scientists within the Duke University School of Medicine and are hopeful our work together may lead to an improvement in the outcome for patients with polytrauma,' commented Dr. James Posada chief executive officer of Resolve Therapeutics. 'Duke Surgery offers a unique environment, coupling state of the art patient care with basic research expertise and infrastructure to enable systematic molecular analysis of plasma-borne inflammatory nucleic acids.' 'Preventing systemic inflammation in polytrauma would be a large step forward in the treatment paradigm for these patients,' said Allan D. Kirk, MD, PhD, Chair of the Department of Surgery at Duke University. 'We look forward to the collaboration with Resolve and learning more about the underlying mechanisms of inflammation in critically injured patients,' he added. About RSLV-132 RSLV-132 is a safe, fully-human, non-immunosuppressive, non-immunogenic, biologic drug with a three-week serum half-life. The drug is comprised of catalytically active human RNase fused to an engineered Fc region of human IgG1. It is designed to remain in circulation and digest extracellular pathogenic RNA in diseases where the presence of cfRNA drives the inflammatory process. RSLV-132 has proven safe in five clinical trials and has demonstrated improvement in autoimmune symptoms in phase 2 clinical trials in both systemic lupus erythematosus and Sjogren's syndrome. About Resolve Therapeutics Resolve is a biopharmaceutical company at the forefront of the emerging field of cell-free nucleic acids in disease. We are developing RSLV-132 and RSLV-145 in a broad range of acute and chronic diseases that are driven by cell-free RNA, cell-free DNA, and Neutrophil Extracellular Traps (NETs). For more information or to discuss our programs please visit:
The Hindu
26-05-2025
- Business
- The Hindu
Lupin, SteinCares ink pact to roll out biosimilar for eye disease in Latin America
Drugmaker Lupin has entered into a licence and supply agreement with SteinCares for commercialisation of its biosimilar ranibizumab across Latin America, excluding Mexico and Argentina. SteinCares, which is specialty healthcare company in Latin America, will handle all regulatory filings, registrations and commercialisation of Ranibizumab in LATAM, while Lupin will be responsible for manufacturing the same, under the agreement, it said on Monday. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). It is used in treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy and Myopic Choroidal Neovascularization, Lupin said. 'Our intent is to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients,' Cyrus Karkaria, president – Biotechnology, Lupin, said in a release. Chief Strategy Officer at SteinCares Sebastian Katz said the company has consistently been the first to market products from highly regulated markets across several countries in the region. The partnership with Lupin strengthens its portfolio and reinforces SteinCares' position as a biosimilar powerhouse in Latin America.
Time of India
26-05-2025
- Business
- Time of India
Lupin inks licensing deal to supply biosimilar ranibizumab in Latin America
Drug maker Lupin on Monday said it has entered into a licence and supply agreement with SteinCares for commercialisation of biosimilar ranibizumab across Latin America , excluding Mexico and Argentina. Under the terms of the agreement, SteinCares will handle all regulatory filings, registrations and commercialisation of Ranibizumab in Latin America, while Lupin will be responsible for manufacturing the same, the Mumbai-based drug maker said in a statement. Ranibizumab is a recombinant humanised IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV). by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Free P2,000 GCash eGift UnionBank Credit Card Apply Now Undo Also Read: Lupin partners with Honeywell for usage of propellant for inhalers "Our intent is to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients," Lupin President Biotechnology Cyrus Karkaria said. Live Events Shares of Lupin were trading 0.32% down at ₹1,972.80 apiece on BSE.
Business Standard
26-05-2025
- Business
- Business Standard
Lupin enters into license and supply agreement with SteinCares
For commercialization of Lupin's biosimilar ranibizumab across Latin America Lupin has entered into a license and supply agreement with SteinCares, a leading specialty healthcare company in Latin America, for commercialization of Lupin's biosimilar ranibizumab across Latin America excluding Mexico and Argentina. Under the terms of the agreement, SteinCares will handle all regulatory filings, registrations and commercialization of Ranibizumab in LATAM, while Lupin will be responsible for manufacturing the same. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV).
Business Upturn
26-05-2025
- Business
- Business Upturn
Lupin and SteinCares sign license and supply agreement for Ranibizumab in Latin America
By Aman Shukla Published on May 26, 2025, 10:31 IST Lupin Limited has signed a license and supply agreement with SteinCares, a Latin America-based specialty healthcare company, for the commercialization of its biosimilar ranibizumab. The agreement covers all Latin American markets except Mexico and Argentina. Under the terms of the agreement, SteinCares will be responsible for regulatory filings, obtaining product registrations, and managing commercialization activities for ranibizumab across the specified LATAM region. Lupin will retain responsibility for manufacturing the biosimilar. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment. It targets and inhibits vascular endothelial growth factor A (VEGF-A), which plays a key role in the formation of abnormal blood vessels in the eye. The biosimilar is used in the treatment of several retinal disorders, including: Neovascular (Wet) Age-Related Macular Degeneration (AMD) Macular Edema Following Retinal Vein Occlusion (RVO) Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Myopic Choroidal Neovascularization (mCNV) The agreement aims to expand access to ophthalmology treatments in Latin America, leveraging SteinCares' regional presence and Lupin's biosimilar capabilities. Dr Cyrus Karkaria, President Biotechnology, Lupin stated, 'Our partnership with SteinCares underscores our commitment to providing innovative, high-quality healthcare solutions to patients in LATAM. Our intent is to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients.' Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
